Skip to main content

Table 4 Immunotherapy in soft tissue sarcomas

From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Study Population Study phase, status Drug and schedule Patients Overall response rate (%)
Mackall et al., 2016 [88] Synovial sarcoma I/II, recruiting NY-ESO-1c259 SPEAR T-cells
Cohort 1 and 2: FL 30 mg/m2/day, day 1–4; CTX 1800 mg/m2/day day 1–2
Cohort 3: CTX 1800 mg/m2/day day 1–2
Cohort 4: FL 30 mg/m2/day, day 1–3; CTX 600 mg/m2/day; day 1–3
Cohort 1: 15
Cohort 2: 2
Cohort 3: 2
Cohort 4: 0
Cohort 1: 50
Cohort 2: NA
Cohort 3: NA
Cohort 4: NA
Italiano et al., 2016 [90] LMS (Arm A), UPS (Arm B), GIST (Arm C), OS (Arm D), other sarcomas (Arm E) II, recruiting in arm B and D Pembrolizumab 200 mg i.v. 3-weekly; CTX 50 mg BID 1week on, 1 week off Arm A: 15
Arm B: 0
Arm C: 10
Arm D: 0
Arm E: 16
No objective responses
Burgess et al., 2016 [89] All-type STS (arm A) and BS (arm B) II, completed Pembrolizumab, 200mg i.v., 3-weekly Arm A: 40
Arm B: 40
Arm A: 17.5
(UPS, LPS, SS)
Arm B: 5 (OS, CS)
Paoluzzi et al., 2016 [91] All-type STS and BS Retrospective Arm A: nivolumab 3 mg/kg i.v., 2-weekly
Arm B: nivolumab 3 mg/kg i.v., 2-weekly + pazopanib 800 mg/day
Arm A: 10
Arm B: 18
Arm A: 10 (CS)
Arm B: 11 (ES, OS)
George et al., 2016 [90] Leiomyosarcoma II Nivolumab 3 mg/kg i.v., 2-weekly 12 No objective responses
  1. BS bone sarcomas; CS chondrosarcoma; CTX cyclophosphamide; ES epithelioid sarcoma; FL fludarabine; GIST Gastrointestinal stromal tumors; LMS leiomyosarcoma; LPS liposarcoma; NA not available; OS osteosarcoma; SS synovial sarcoma; STS soft tissue sarcomas; UPS undifferentiated pleomorphic sarcoma
\